Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 49, Issue 18, Pages 5513-5523Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm060413w
Keywords
-
Categories
Funding
- NCI NIH HHS [1R01 CA098945] Funding Source: Medline
Ask authors/readers for more resources
3-[5-{2-(2,3-Dihydroxyprop-1-yl)-o-carboran-1-yl} pentan-1-yl] thymidine (compound 1, N5-2OH) belongs to a novel class of boron delivery agents for neutron capture therapy, which was designated 3-carboranylthymidine analogue (3CTAs). Two shorter and more convenient synthetic routes were developed for the synthesis of 1 in the B-10-enriched form, which is necessary for its preclinical and clinical evaluation in neutron irradiation studies. For more insight on structure-activity relationships, various stereochemical and geometrical isomers of 1 were synthesized and their specificities as substrate for human thymidine kinase 1 (hTK1) were evaluated. A computational model for the binding of various isomers of 1 to the active site of hTK1 was developed. Preliminary studies carried out in F98 glioma bearing rats that had received a B-10-enriched form of 1 followed by neutron irradiation demonstrated a significant prolongation in survival times compared to control animals, suggesting that further studies are warranted to evaluate the therapeutic potential of 1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available